Emmaus Medical, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative treatments and therapies primarily for rare and orphan disease. We are currently focused on sickle cell disease (SCD), a genetic disorder with a significant unmet medical need. Our lead product, Endari® (L-glutamine oral powder), received FDA approval on July 7, 2017. With this approval, Endari® is available to reduce the acute complications of sickle cell disease in adults and children 5 years and older. For more information, please read the Full Prescribing Information for Endari® at http://www.EndariRx.com.
.